Bristol-Myers Squibb expands AI-driven trial work, shares react to oncology focus

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-27, 14:44.

Bristol-Myers Squibb (US1078421011) is deepening its use of artificial intelligence in clinical trial design across oncology and neurology. The New York Stock Exchange-listed group is extending work with Tempus AI on program selection and patient matching, according to recent market commentary from Bloomberg and TrendSpider.

AI partnership in trials

In late June 2026, Tempus AI disclosed that Bristol-Myers Squibb is expanding AI-driven trial design efforts across oncology and Alzheimer’s programs, using real-world data to support protocol optimisation and recruitment. TrendSpider summary of Tempus AI and Bristol-Myers Squibb collaboration The collaboration focuses on identifying suitable patient cohorts and refining endpoints to shorten timelines in complex studies.

The partnership underlines Bristol-Myers Squibb’s strategy to support its late-stage pipeline with more efficient evidence generation in cancer and neurodegeneration. According to commentary citing Bloomberg, the work with Tempus AI is positioned as a way to contain development risk while preserving the value of high-cost assets in areas such as immuno-oncology. Bloomberg report on Tempus AI trial design expansion

Regulatory and earnings backdrop

The regulatory environment for Bristol-Myers Squibb remains demanding after the US Supreme Court declined to hear challenges from several drugmakers against Medicare’s drug price negotiation framework, a decision that keeps pressure on margins for top-selling therapies. Bloomberg coverage of Medicare negotiation ruling The group is among large-cap US pharmaceuticals adapting commercial strategies to the negotiated pricing regime.

Despite that backdrop, Bristol-Myers Squibb reported better-than-expected first quarter 2026 figures, with growth brands driving revenue while legacy products faced continued generic competition. Reuters report on Q1 2026 results The company reaffirmed its full-year 2026 adjusted EPS and sales guidance, signalling confidence in its portfolio transition and cost management.

The therapies behind the stock

Bristol-Myers Squibb generates most of its revenue from innovative prescription medicines in oncology, hematology, cardiovascular and immunology. Key marketed brands include Opdivo for cancer immunotherapy, Eliquis in stroke prevention for atrial fibrillation, and Abecma in multiple myeloma, alongside a broad pipeline of cell therapies and targeted agents Bristol-Myers Squibb company and portfolio overview.

Where the shares trade today

As of 2026-06-26, 20:00, Bristol-Myers Squibb shares (US1078421011) trade on the New York Stock Exchange at approximately 57.41 USD, based on recent data from TrendSpider and US exchange feeds. TrendSpider price and technical snapshot for BMY

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on sources believed to be reliable but cannot be guaranteed.